Literature DB >> 22178578

Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis.

Cristina P Vicente1, Hartmut Weiler, Enrico Di Cera, Douglas M Tollefsen.   

Abstract

INTRODUCTION: The thrombin mutant W215A/E217A (WE thrombin) has greatly reduced procoagulant activity, but it activates protein C in the presence of thrombomodulin and inhibits binding of platelet glycoprotein Ib to von Willebrand factor and collagen under flow conditions. Both thrombomodulin-dependent protein C activation and inhibition of platelet adhesion could contribute to the antithrombotic activity of WE thrombin.
MATERIALS AND METHODS: To assess the role of thrombomodulin, we administered WE thrombin to thrombomodulin-deficient (TM(Pro/Pro)) mice and measured the time to occlusive thrombus formation in the carotid artery after photochemical injury of the endothelium. RESULTS AND
CONCLUSIONS: Doses of WE thrombin ≥10μg/kg prolonged the thrombosis time of wild-type mice (>1.6-fold), while doses ≥100μg/kg only slightly prolonged the thrombosis time of TM(Pro/Pro) mice. We conclude that thrombomodulin plays a predominate role in mediating the antithrombotic effect of WE thrombin in the arterial circulation of mice after endothelial injury. Thrombomodulin-independent effects may occur only when high doses of WE thrombin are administered.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178578      PMCID: PMC3461961          DOI: 10.1016/j.thromres.2011.11.026

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  17 in total

1.  Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.

Authors:  Michelle A Berny-Lang; Sawan Hurst; Erik I Tucker; Leslie A Pelc; Ruikang K Wang; Patricia D Hurn; Enrico Di Cera; Owen J T McCarty; András Gruber
Journal:  Stroke       Date:  2011-04-21       Impact factor: 7.914

2.  Heparin cofactor II inhibits arterial thrombosis after endothelial injury.

Authors:  Li He; Cristina P Vicente; Randal J Westrick; Daniel T Eitzman; Douglas M Tollefsen
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

3.  Protein engineering thrombin for optimal specificity and potency of anticoagulant activity in vivo.

Authors:  M Tsiang; L R Paborsky; W X Li; A K Jain; C T Mao; K E Dunn; D W Lee; S Y Matsumura; M D Matteucci; S E Coutré; L L Leung; C S Gibbs
Journal:  Biochemistry       Date:  1996-12-24       Impact factor: 3.162

4.  A targeted point mutation in thrombomodulin generates viable mice with a prethrombotic state.

Authors:  H Weiler-Guettler; P D Christie; D L Beeler; A M Healy; W W Hancock; H Rayburn; J M Edelberg; R D Rosenberg
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

5.  Characterization of a mouse model for thrombomodulin deficiency.

Authors:  H Weiler; V Lindner; B Kerlin; B H Isermann; S B Hendrickson; B C Cooley; D A Meh; M W Mosesson; N W Shworak; M J Post; E M Conway; L H Ulfman; U H von Andrian; J I Weitz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2001-09       Impact factor: 8.311

6.  Rational design of a potent anticoagulant thrombin.

Authors:  A M Cantwell; E Di Cera
Journal:  J Biol Chem       Date:  2000-12-22       Impact factor: 5.157

Review 7.  Mouse models of thrombosis: thrombomodulin.

Authors:  Hartmut Weiler
Journal:  Thromb Haemost       Date:  2004-09       Impact factor: 5.249

8.  Single amino acid substitutions dissociate fibrinogen-clotting and thrombomodulin-binding activities of human thrombin.

Authors:  Q Y Wu; J P Sheehan; M Tsiang; S R Lentz; J J Birktoft; J E Sadler
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

9.  The thrombin mutant W215A/E217A shows safe and potent anticoagulant and antithrombotic effects in vivo.

Authors:  Andras Gruber; Angelene M Cantwell; Enrico Di Cera; Stephen R Hanson
Journal:  J Biol Chem       Date:  2002-06-17       Impact factor: 5.157

10.  The contributions of the alpha 2 beta 1 integrin to vascular thrombosis in vivo.

Authors:  Li He; Loretta K Pappan; David G Grenache; Zhengzhi Li; Douglas M Tollefsen; Samuel A Santoro; Mary M Zutter
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

View more
  6 in total

1.  How Thrombomodulin Enables W215A/E217A Thrombin to Cleave Protein C but Not Fibrinogen.

Authors:  Riley B Peacock; Taylor McGrann; Sofia Zaragoza; Elizabeth A Komives
Journal:  Biochemistry       Date:  2022-01-03       Impact factor: 3.321

2.  Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis.

Authors:  Norah G Verbout; Xiaolin Yu; Laura D Healy; Kevin G Phillips; Erik I Tucker; András Gruber; Owen J T McCarty; Halina Offner
Journal:  Metab Brain Dis       Date:  2014-05-09       Impact factor: 3.584

3.  The protein C activator AB002 rapidly interrupts thrombus development in baboons.

Authors:  Erik I Tucker; Norah G Verbout; Brandon D Markway; Michael Wallisch; Christina U Lorentz; Monica T Hinds; Joseph J Shatzel; Leslie A Pelc; David C Wood; Owen J T McCarty; Enrico Di Cera; András Gruber
Journal:  Blood       Date:  2020-02-27       Impact factor: 22.113

Review 4.  Thrombin generation and activity in multiple sclerosis.

Authors:  Kelley R Jordan; Ivan Parra-Izquierdo; András Gruber; Joseph J Shatzel; Peter Pham; Larry S Sherman; Owen J T McCarty; Norah G Verbout
Journal:  Metab Brain Dis       Date:  2021-01-07       Impact factor: 3.584

5.  Rational Design of Protein C Activators.

Authors:  Sergio Barranco-Medina; Mary Murphy; Leslie Pelc; Zhiwei Chen; Enrico Di Cera; Nicola Pozzi
Journal:  Sci Rep       Date:  2017-03-15       Impact factor: 4.379

6.  Defective fibrin deposition and thrombus stability in Bambi-/- mice are mediated by elevated anticoagulant function.

Authors:  James T B Crawley; Argita Zalli; James H Monkman; Anastasis Petri; David A Lane; Josefin Ahnstrom; Isabelle I Salles-Crawley
Journal:  J Thromb Haemost       Date:  2019-08-26       Impact factor: 5.824

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.